Literature DB >> 32556131

Inverting the BTK-BCL2 order.

Jennifer R Brown1.   

Abstract

Entities:  

Year:  2020        PMID: 32556131      PMCID: PMC7316207          DOI: 10.1182/blood.2020005886

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors:  Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Cancer Discov       Date:  2018-12-04       Impact factor: 39.397

2.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

3.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Authors:  Kami J Maddocks; Amy S Ruppert; Gerard Lozanski; Nyla A Heerema; Weiqiang Zhao; Lynne Abruzzo; Arletta Lozanski; Melanie Davis; Amber Gordon; Lisa L Smith; Rose Mantel; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Leslie A Andritsos; Farrukh Awan; Kristie A Blum; Michael R Grever; Amy J Johnson; John C Byrd; Jennifer A Woyach
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

4.  BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.

Authors:  Victor S Lin; Thomas E Lew; Sasanka M Handunnetti; Piers Blombery; Tamia Nguyen; David A Westerman; Bryone J Kuss; Constantine S Tam; Andrew W Roberts; John F Seymour; Mary Ann Anderson
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

5.  Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Authors:  Romain Guièze; Vivian M Liu; Daniel Rosebrock; Alexis A Jourdain; María Hernández-Sánchez; Aina Martinez Zurita; Jing Sun; Elisa Ten Hacken; Kaitlyn Baranowski; Philip A Thompson; Jin-Mi Heo; Zachary Cartun; Ozan Aygün; J Bryan Iorgulescu; Wandi Zhang; Giulia Notarangelo; Dimitri Livitz; Shuqiang Li; Matthew S Davids; Anat Biran; Stacey M Fernandes; Jennifer R Brown; Ana Lako; Zoe B Ciantra; Matthew A Lawlor; Derin B Keskin; Namrata D Udeshi; William G Wierda; Kenneth J Livak; Anthony G Letai; Donna Neuberg; J Wade Harper; Steven A Carr; Federica Piccioni; Christopher J Ott; Ignaty Leshchiner; Cory M Johannessen; John Doench; Vamsi K Mootha; Gad Getz; Catherine J Wu
Journal:  Cancer Cell       Date:  2019-09-19       Impact factor: 31.743

6.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Authors:  Jeffrey A Jones; Anthony R Mato; William G Wierda; Matthew S Davids; Michael Choi; Bruce D Cheson; Richard R Furman; Nicole Lamanna; Paul M Barr; Lang Zhou; Brenda Chyla; Ahmed Hamed Salem; Maria Verdugo; Rod A Humerickhouse; Jalaja Potluri; Steven Coutre; Jennifer Woyach; John C Byrd
Journal:  Lancet Oncol       Date:  2017-12-12       Impact factor: 41.316

7.  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff P Sharman; William Wierda; Weiqiang Zhao; Nyla A Heerema; Ying Luan; Emily A Liu; James P Dean; Susan O'Brien
Journal:  Clin Cancer Res       Date:  2020-03-24       Impact factor: 12.531

8.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Authors:  Carmen D Herling; Nima Abedpour; Jonathan Weiss; Anna Schmitt; Ron Daniel Jachimowicz; Olaf Merkel; Maria Cartolano; Sebastian Oberbeck; Petra Mayer; Valeska Berg; Daniel Thomalla; Nadine Kutsch; Marius Stiefelhagen; Paula Cramer; Clemens-Martin Wendtner; Thorsten Persigehl; Andreas Saleh; Janine Altmüller; Peter Nürnberg; Christian Pallasch; Viktor Achter; Ulrich Lang; Barbara Eichhorst; Roberta Castiglione; Stephan C Schäfer; Reinhard Büttner; Karl-Anton Kreuzer; Hans Christian Reinhardt; Michael Hallek; Lukas P Frenzel; Martin Peifer
Journal:  Nat Commun       Date:  2018-02-20       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.